171 related articles for article (PubMed ID: 38074508)
1. Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice.
Kunst RF; Bolt I; van Dasselaar RDJ; Nijmeijer BA; Beuers U; Oude Elferink RPJ; van de Graaf SFJ
JHEP Rep; 2024 Jan; 6(1):100917. PubMed ID: 38074508
[TBL] [Abstract][Full Text] [Related]
2. Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice.
Kunst RF; de Waart DR; Wolters F; Duijst S; Vogels EW; Bolt I; Verheij J; Beuers U; Oude Elferink RPJ; van de Graaf SFJ
JHEP Rep; 2022 Nov; 4(11):100573. PubMed ID: 36160754
[TBL] [Abstract][Full Text] [Related]
3. Effects of apical sodium-bile acid transporter inhibitor and obeticholic acid co-treatment in experimental non-alcoholic steatohepatitis.
Matye DJ; Qin X; Hasan MN; Gu L; Clayton YD; Li F; Li T
Liver Res; 2022 Dec; 6(4):276-283. PubMed ID: 36819659
[TBL] [Abstract][Full Text] [Related]
4. Attenuation of the Hepatoprotective Effects of Ileal Apical Sodium Dependent Bile Acid Transporter (ASBT) Inhibition in Choline-Deficient L-Amino Acid-Defined (CDAA) Diet-Fed Mice.
Rao A; van de Peppel IP; Gumber S; Karpen SJ; Dawson PA
Front Med (Lausanne); 2020; 7():60. PubMed ID: 32158763
[TBL] [Abstract][Full Text] [Related]
5. Differential and organ-specific functions of organic solute transporter α and β in experimental cholestasis.
van de Wiel SMW; Porteiro B; Belt SC; Vogels EWM; Bolt I; Vermeulen JLM; de Waart DR; Verheij J; Muncan V; Oude Elferink RPJ; van de Graaf SFJ
JHEP Rep; 2022 May; 4(5):100463. PubMed ID: 35462858
[TBL] [Abstract][Full Text] [Related]
6. Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases.
Sanyal AJ; Ling L; Beuers U; DePaoli AM; Lieu HD; Harrison SA; Hirschfield GM
JHEP Rep; 2021 Jun; 3(3):100255. PubMed ID: 33898959
[TBL] [Abstract][Full Text] [Related]
7. Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the
Fuchs CD; Sroda N; Scharnagl H; Gupta R; Minto W; Stojakovic T; Liles JT; Budas G; Hollenback D; Trauner M
JHEP Rep; 2023 Nov; 5(11):100874. PubMed ID: 37841639
[TBL] [Abstract][Full Text] [Related]
8. Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis.
Meadows V; Marakovits C; Ekser B; Kundu D; Zhou T; Kyritsi K; Pham L; Chen L; Kennedy L; Ceci L; Wu N; Carpino G; Zhang W; Isidan A; Meyer A; Owen T; Gaudio E; Onori P; Alpini G; Francis H
Am J Physiol Gastrointest Liver Physiol; 2023 Jan; 324(1):G60-G77. PubMed ID: 36410025
[TBL] [Abstract][Full Text] [Related]
9. Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis.
Matye DJ; Wang H; Luo W; Sharp RR; Chen C; Gu L; Jones KL; Ding WX; Friedman JE; Li T
Cell Mol Gastroenterol Hepatol; 2021; 12(3):1001-1019. PubMed ID: 33965587
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice.
Rao A; Kosters A; Mells JE; Zhang W; Setchell KD; Amanso AM; Wynn GM; Xu T; Keller BT; Yin H; Banton S; Jones DP; Wu H; Dawson PA; Karpen SJ
Sci Transl Med; 2016 Sep; 8(357):357ra122. PubMed ID: 27655848
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.
Baghdasaryan A; Fuchs CD; Österreicher CH; Lemberger UJ; Halilbasic E; Påhlman I; Graffner H; Krones E; Fickert P; Wahlström A; Ståhlman M; Paumgartner G; Marschall HU; Trauner M
J Hepatol; 2016 Mar; 64(3):674-81. PubMed ID: 26529078
[TBL] [Abstract][Full Text] [Related]
12. SC-435, an ileal apical sodium co-dependent bile acid transporter (ASBT) inhibitor lowers plasma cholesterol and reduces atherosclerosis in guinea pigs.
West KL; Zern TL; Butteiger DN; Keller BT; Fernandez ML
Atherosclerosis; 2003 Dec; 171(2):201-10. PubMed ID: 14644388
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the renal apical sodium dependent bile acid transporter prevents cholemic nephropathy in mice with obstructive cholestasis.
Ghallab A; González D; Strängberg E; Hofmann U; Myllys M; Hassan R; Hobloss Z; Brackhagen L; Begher-Tibbe B; Duda JC; Drenda C; Kappenberg F; Reinders J; Friebel A; Vucur M; Turajski M; Seddek AL; Abbas T; Abdelmageed N; Morad SAF; Morad W; Hamdy A; Albrecht W; Kittana N; Assali M; Vartak N; van Thriel C; Sous A; Nell P; Villar-Fernandez M; Cadenas C; Genc E; Marchan R; Luedde T; Åkerblad P; Mattsson J; Marschall HU; Hoehme S; Stirnimann G; Schwab M; Boor P; Amann K; Schmitz J; Bräsen JH; Rahnenführer J; Edlund K; Karpen SJ; Simbrunner B; Reiberger T; Mandorfer M; Trauner M; Dawson PA; Lindström E; Hengstler JG
J Hepatol; 2024 Feb; 80(2):268-281. PubMed ID: 37939855
[TBL] [Abstract][Full Text] [Related]
14. SC-435, an ileal apical sodium-codependent bile acid transporter inhibitor alters mRNA levels and enzyme activities of selected genes involved in hepatic cholesterol and lipoprotein metabolism in guinea pigs.
West KL; McGrane M; Odom D; Keller B; Fernandez ML
J Nutr Biochem; 2005 Dec; 16(12):722-8. PubMed ID: 16169202
[TBL] [Abstract][Full Text] [Related]
15. Combining ASBT inhibitor and FGF15 treatments enhances therapeutic efficacy against cholangiopathy in female but not male Cyp2c70 KO mice.
Hasan MN; Chen J; Matye D; Wang H; Luo W; Gu L; Clayton YD; Du Y; Li T
J Lipid Res; 2023 Mar; 64(3):100340. PubMed ID: 36737039
[TBL] [Abstract][Full Text] [Related]
16. A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multiorgan activity and shows translational relevance to humans.
Caballero-Camino FJ; Rodrigues PM; Wångsell F; Agirre-Lizaso A; Olaizola P; Izquierdo-Sanchez L; Perugorria MJ; Bujanda L; Angelin B; Straniero S; Wallebäck A; Starke I; Gillberg PG; Strängberg E; Bonn B; Mattsson JP; Madsen MR; Hansen HH; Lindström E; Åkerblad P; Banales JM
Hepatology; 2023 Sep; 78(3):709-726. PubMed ID: 36999529
[TBL] [Abstract][Full Text] [Related]
17. Defective FXR-FGF15 signaling and bile acid homeostasis in cystic fibrosis mice can be restored by the laxative polyethylene glycol.
Bertolini A; van de Peppel IP; Doktorova-Demmin M; Bodewes FAJA; de Jonge H; Bijvelds M; Verkade HJ; Jonker JW
Am J Physiol Gastrointest Liver Physiol; 2019 Mar; 316(3):G404-G411. PubMed ID: 30653340
[TBL] [Abstract][Full Text] [Related]
18. Melatonin improves cholestatic liver disease via the gut-liver axis.
Liu X; Li J; Shi M; Fu J; Wang Y; Kang W; Liu J; Zhu F; Huang K; Chen X; Liu Y
J Pineal Res; 2024 Jan; 76(1):e12929. PubMed ID: 38047407
[TBL] [Abstract][Full Text] [Related]
19. Unaltered Liver Regeneration in Post-Cholestatic Rats Treated with the FXR Agonist Obeticholic Acid.
de Haan LR; Verheij J; van Golen RF; Horneffer-van der Sluis V; Lewis MR; Beuers UHW; van Gulik TM; Olde Damink SWM; Schaap FG; Heger M; Olthof PB
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33578971
[No Abstract] [Full Text] [Related]
20. Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis.
Hruz P; Zimmermann C; Gutmann H; Degen L; Beuers U; Terracciano L; Drewe J; Beglinger C
Gut; 2006 Mar; 55(3):395-402. PubMed ID: 16150853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
